- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves New Type 2 Diabetes Drugs
Medications expected to improve blood sugar control in children 10 years and older.
Earlier this week, the FDA announced the approval of Jardiance and Synjardy, created as additions to diet and exercise for pediatric type 2 diabetes. Reportedly, these approvals offer a new class of oral medicines for the treatment of type two diabetes in children.
Empagliflozin, the active ingredient in Jardiance and Synjardy, works by increasing the excretion of glucose in the urine.
"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidly in children," said Michelle Carey, MD, MPH, associate director for therapeutic review for the division of diabetes, lipid disorders, and obesity in the FDA's Center for Drug Evaluation and Research. "Today's approvals provide much-needed additional treatment options for children with type 2 diabetes."
Reference: FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes. PR Newswire. June 20, 2023. Accessed June 23, 2023. https://www.prnewswire.com/news-releases/fda-approves-new-class-of-medicines-to-treat-pediatric-type-2-diabetes-301855985.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
